CORNERSTONE THERAPEUTICS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|
| Revenue | $116.1M | $101.4M | $125.3M | $109.6M |
| Operating income | −$3.0M | $2.5M | $7.9M | $15.9M |
| Net income | −$1.8M | $1.7M | $6.2M | $10.2M |
| Total assets | $369.4M | $232.3M | $285.5M | — |
| Total liabilities | $203.2M | $57.5M | $113.1M | — |
| Equity | $166.2M | $174.8M | $172.4M | $163.9M |
| EPS (diluted) | $-0.07 | $0.07 | $0.24 | $0.54 |
| Shares out. | 26.0M | 25.8M | 25.5M | 18.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2012- Operating margin
- −2.6%
- Net margin
- −1.6%
- Return on equity
- −1.1%
- Return on assets
- −0.5%
- Return on capital (ROCE)
- −1.0%
- Liabilities / assets
- 55.0%
- Debt / equity
- 1.22×
- Book value / share
- $6.39
- Revenue growth (YoY)
- 14.5%
- Net income growth (YoY)
- −204.8%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2012- Altman Z″ (distress)
- 1.43grey zone
- Accruals / assets
- −5.5%clean
- Beneish M-Score
- -2.81normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Altman Z″ in the grey zone
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 13, 2008
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- PROPOXYPHENE NAPSYLATE AND ACETAMINOPHENMay 7, 2004
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Chiesi Farmaceutici Spa10% owner | Feb 3, 2014 | Buy | 11.5M | $9.50 |
| Roberts AlanOfficer — VP, Scientific Affairs | Feb 3, 2014 | D | 62,572 | $9.50 |
| Mcewan Alastair StuartOfficer — CFO and Treasurer | Feb 3, 2014 | D | 272,241 | $9.50 |
| Mcbean KennethOfficer — President | Feb 3, 2014 | D | 21,955 | $9.50 |
| Maetzel AndreasOfficer — VP, Clinical and Regulatory | Feb 3, 2014 | D | 25,000 | $9.50 |
| Franklin Joshua BOfficer — VP, Strategy & Bus. Dev. | Feb 3, 2014 | D | 20,944 | $9.50 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder vote · Other material eventFeb 4, 2014
- Shareholder vote · Other material eventFeb 3, 2014
- Results of operationsNov 7, 2013
- Shareholder voteOct 31, 2013
- Director / officer changeSep 19, 2013
- Amended charter or bylaws · Other material eventSep 16, 2013
- Entered a material agreement · Other material eventSep 16, 2013
- Other material eventAug 20, 2013
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GFeb 14, 2014
- S-8 POSS-8 POS 333-168542Feb 12, 2014
- S-8 POSS-8 POS 333-161326Feb 12, 2014
- S-8 POSS-8 POS 333-156293Feb 12, 2014
- S-8 POSS-8 POS 333-133867Feb 12, 2014
- S-8 POSS-8 POS 333-131037Feb 12, 2014
- S-8 POSS-8 POS 333-125892Feb 12, 2014
- S-8 POSS-8 POS 333-119409Feb 12, 2014
- SC 13D/ASCHEDULE 13D AMENDMENT NO. 7Feb 7, 2014
- RWWITHDRAWAL REQUEST - S-3 FILE NO. 333-166770Feb 5, 2014
- SC 13D/AFeb 4, 2014
- 4Feb 4, 2014
- 4FORM 4 SUBMISSIONFeb 4, 2014
- 4FORM 4 SUBMISSIONFeb 4, 2014
- 4FORM 4 SUBMISSIONFeb 4, 2014
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.